Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.42 and traded as high as $1.44. Atossa Therapeutics shares last traded at $1.44, with a volume of 357,218 shares trading hands.
Analysts Set New Price Targets
ATOS has been the subject of several recent research reports. StockNews.com downgraded shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, August 12th. Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Atossa Therapeutics in a report on Thursday, June 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $6.00 price objective on shares of Atossa Therapeutics in a research note on Monday, August 12th.
Read Our Latest Stock Analysis on ATOS
Atossa Therapeutics Stock Performance
The firm has a market capitalization of $181.09 million, a price-to-earnings ratio of -6.00 and a beta of 1.20. The firm has a fifty day moving average price of $1.38 and a 200 day moving average price of $1.42.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Research analysts predict that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in shares of Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company's stock worth $490,000 after acquiring an additional 399,041 shares during the period. Cetera Advisors LLC purchased a new position in shares of Atossa Therapeutics in the first quarter valued at $72,000. Virtu Financial LLC acquired a new position in shares of Atossa Therapeutics during the 1st quarter worth $151,000. Rhumbline Advisers purchased a new stake in shares of Atossa Therapeutics in the 2nd quarter worth about $161,000. Finally, Vanguard Group Inc. boosted its position in shares of Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company's stock worth $10,357,000 after buying an additional 78,269 shares in the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Read More
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
